Page last updated: 2024-11-04

tulobuterol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5606
CHEMBL ID1159717
CHEBI ID93856
SCHEMBL ID122692
MeSH IDM0056604

Synonyms (80)

Synonym
BRD-A37441042-003-02-2
KBIO1_000712
DIVK1C_000712
SPECTRUM_001648
tulobuterolum [inn-latin]
2-tert-butylamino-1-(2-chlorphenyl)ethanol
alpha-((tert-butylamino)methyl)-o-chlorobenzyl alcohol
2-chloro-alpha-(((1,1-dimethylethyl)amino)methyl)benzenemethanol
tulobuterol
IDI1_000712
BSPBIO_003440
tulobuterol (jp17/inn)
atenos (tn)
41570-61-0
D02151
KBIOGR_000811
KBIOSS_002128
KBIO2_007264
KBIO2_004696
KBIO2_002128
KBIO3_002943
SPECTRUM3_001900
SPECTRUM2_001616
SPBIO_001651
SPECTRUM4_000206
NINDS_000712
SPECTRUM5_001285
LOPAC0_001149
NCGC00162354-01
L013403
HMS2090E11
NCGC00016034-03
VU0244437-2
CHEMBL1159717
nsc-758643
2-(tert-butylamino)-1-(2-chlorophenyl)ethanol
unii-591i9su0f7
tulobuterolum
591i9su0f7 ,
nsc 758643
tulobuterol [inn:ban:jan]
CCG-205223
NCGC00016034-02
AKOS010122688
bdbm50421717
(+/-)-tulobuterol
hn 078
tulobuterol [who-dd]
tulobuterol [jan]
tulobuterol [inn]
.alpha.-((tert-butylamino)methyl)-o-chlorobenzyl alcohol
tulobuterol [mi]
SCHEMBL122692
AB00053692-02
DTXSID7048457
Q-201905
.alpha.-[(tert-butylamino)methyl]-o-chlorobenzyl alcohol
2-(tert-butylamino)-1-(2-chlorophenyl)ethanol #
2-chloro-.alpha.-[[(1,1-dimethylethyl)amino]methyl]benzenemethanol
AB00053692_03
2-(tert-butylamino)-1-(2-chlorophenyl)ethan-1-ol
CHEBI:93856
EN300-718088
2-chloro-alpha-[[(1,1-dimethylethyl)amino]methyl]benzenemethanol
SR-01000076165-4
SBI-0051116.P003
HMS3715J21
DB12248
CS-0013856
HY-B1810
F17342
(rs)-2-tert-butylamino-1 -phenil ethanol monohydrochloride; o-chloro-?-[(tert-butylamino)methyl]benzyl alcohol hydrochloride; (+/-)-tulobuterol hydrochloride
AS-10998
Q909353
AMY11155
SDCCGSBI-0051116.P004
1-(2-chlorophenyl)-2-[[1,1,1,3,3,3-hexadeuterio-2-(trideuteriomethyl)propan-2-yl]amino]ethanol
NCGC00016034-09
c-78 (free base)
tulobuterol 1000 microg/ml in acetonitrile

Research Excerpts

Overview

Tulobuterol is a beta(2)-adrenergic agonist with a favorable pharmacokinetic profile used for asthma management in Japan. The drug is a new synthetic beta 2-agonist with potent and prolonged bronchodilator activity when given by oral and inhaled routes.

ExcerptReferenceRelevance
"Tulobuterol is a selective β2-adrenoceptor agonist, widely used safely as bronchodilator in children."( A Case of Congenital Complete Atrioventricular Block Treated with Transdermal Tulobuterol.
Ashina, M; Deguchi, M; Fujioka, K; Fukushima, S; Iijima, K; Ikuta, T; Morioka, I; Morizane, M; Ohyama, S; Okubo, S; Sato, Y; Tanimura, K; Yamada, H; Yamana, K, 2018
)
1.43
"Tulobuterol is a β2-adrenergic agonist that was the first bronchodilator approved as a transdermal patch for humans. "( The pharmacokinetics of the β2-adrenoceptor agonist, tulobuterol, in Beagle dogs following transdermal and intravenous administration.
Choi, YJ; Kang, JH; Kim, JH; Kim, TH; Koo, TS; Park, HJ; Seo, KW; Song, KH, 2016
)
2.13
"The tulobuterol patch (TP) is a beta(2)-adrenergic agonist with a favorable pharmacokinetic profile used for asthma management in Japan. "( Effects of the tulobuterol patch on the treatment of acute asthma exacerbations in young children.
Akashi, K; Daikoku, K; Doi, S; Ebisawa, M; Fujisawa, T; Hamasaki, Y; Imamura, N; Katsunuma, T; Kitabayashi, T; Kondo, N; Kurihara, K; Masuda, K; Morikawa, A; Nishima, S; Nishimuta, T; Noma, T; Ohya, Y; Terada, A; Watanabe, K; Watanabe, T; Yamada, M; Yamada, T; Yoshihara, S,
)
1.04
"Tulobuterol tape is a newly formulated, effective and safe medication for the treatment of asthma."( [The efficacy and safety of tulobuterol tape in mild and moderate persistent asthma patients].
Cao, ZL; Chen, BY; Chen, X; He, J; He, QY; Lin, JT; Su, N; Xiao, Y; Yan, XX; Yang, M, 2007
)
2.08
"Tulobuterol is a synthetic beta-adrenergic agonist which, when administered orally, is a potent, long-acting bronchodilator. "( Can a new beta 2-agonist reduce the mortality of asthma?
Aldons, PM, 1990
)
1.72
"Tulobuterol is a new synthetic beta 2-agonist with potent and prolonged bronchodilator activity when given by oral and inhaled routes."( Prolonged treatment with oral and inhaled tulobuterol does not induce airways tachyphlaxis.
Patel, KR, 1990
)
1.26

Actions

ExcerptReferenceRelevance
"Tulobuterol does not activate beta-1 adrenoceptors and has no direct positive chronotropic effect."( Beta-2 adrenergic responses to tulobuterol in airway smooth muscle, vascular smooth muscle and adrenergic nerves.
Edoute, Y; Flavahan, NA; Ruff, F; Santais, MC; Vanhoutte, PM; Verbeuren, TJ; Zander, JF, 1988
)
1.28

Treatment

ExcerptReferenceRelevance
"Tulobuterol treatment was withdrawn in one patient because of severe vomiting and headache of unknown cause."( Treatment of asthma with tulobuterol or albuterol in school-age children.
Chauvin, JP; de Blic, J; Le Bourgeois, M; Paupe, J; Scheinmann, P,
)
1.16

Toxicity

Tulobuterol tape is a newly formulated, effective and safe medication for the treatment of asthma. In preschool children undergoing tonsillectomy, the preoperative application of a tulobuterl patch could decrease the occurrence of perioperative respiratory adverse events. The incidence of adverse reactions including palpitations and tremor in the tulobuters group was significantly lower than that in the tablet group.

ExcerptReferenceRelevance
"Tulobuterol tape is a newly formulated, effective and safe medication for the treatment of asthma."( [The efficacy and safety of tulobuterol tape in mild and moderate persistent asthma patients].
Cao, ZL; Chen, BY; Chen, X; He, J; He, QY; Lin, JT; Su, N; Xiao, Y; Yan, XX; Yang, M, 2007
)
2.08
"Aggravation of asthmatic response (asthmatic attack, 2 cases) and adverse events (tremor, 1 case) due to a switch from a brand-name tulobuterol tape to a generic tape were recently reported."( [Questionnaire survey on the change of asthmatic response, adverse events and product usability due to drug switching between name-brand and generic tulobuterol tapes].
Hori, S; Izumi, T; Miki, A; Satoh, H; Sawada, Y, 2012
)
0.78
" The two groups were compared with respect to symptom scores of cough, wheeze, respiratory rate, wheezing sound, three depression sign and peak expiratory flow, as well as adverse events."( [Efficacy and safety of tulobuterol patch versus oral salbutamol sulfate in children with mild or moderate acute attack of bronchial asthma: a comparative study].
Bao, YX; Lin, Q; Liu, QH, 2013
)
0.7
" One child developed hand trembling in the salbutamol group, while no adverse event occurred in the tulobuterol group."( [Efficacy and safety of tulobuterol patch versus oral salbutamol sulfate in children with mild or moderate acute attack of bronchial asthma: a comparative study].
Bao, YX; Lin, Q; Liu, QH, 2013
)
0.91
" In the present study, safe and effective ionic liquids for transdermal absorption were obtained as salts generated by a neutralization reaction between highly biocompatible aliphatic carboxylic acids (octanoic acid or isostearic acid) and aliphatic amines (diisopropanolamine or triisopropanolamine) (Medrx Co."( The molecular assembly of the ionic liquid/aliphatic carboxylic acid/aliphatic amine as effective and safety transdermal permeation enhancers.
Kubota, K; Shibata, A; Yamaguchi, T, 2016
)
0.43
"Perioperative respiratory adverse events are common in children."( Effect of Tulobuterol Patch Versus Placebo on the Occurrence of Respiratory Adverse Events in Children Undergoing Tonsillectomies: A Randomized Controlled Trial.
Jang, YE; Ji, SH; Kang, P; Kim, EH; Kim, HS; Kim, JK; Kim, JT; Lee, JH; Lee, SH; Park, JB; Park, YH, 2023
)
1.31
" The primary outcome was the occurrence of any perioperative respiratory adverse events: oxygen desaturation <95%, airway obstruction, laryngospasm, bronchospasm, severe coughing, or stridor."( Effect of Tulobuterol Patch Versus Placebo on the Occurrence of Respiratory Adverse Events in Children Undergoing Tonsillectomies: A Randomized Controlled Trial.
Jang, YE; Ji, SH; Kang, P; Kim, EH; Kim, HS; Kim, JK; Kim, JT; Lee, JH; Lee, SH; Park, JB; Park, YH, 2023
)
1.31
" The incidence of any perioperative respiratory adverse event was lower with tulobuterol (n = 13/88; 14."( Effect of Tulobuterol Patch Versus Placebo on the Occurrence of Respiratory Adverse Events in Children Undergoing Tonsillectomies: A Randomized Controlled Trial.
Jang, YE; Ji, SH; Kang, P; Kim, EH; Kim, HS; Kim, JK; Kim, JT; Lee, JH; Lee, SH; Park, JB; Park, YH, 2023
)
1.54
"In preschool children undergoing tonsillectomy, the preoperative application of a tulobuterol patch could decrease the occurrence of perioperative respiratory adverse events."( Effect of Tulobuterol Patch Versus Placebo on the Occurrence of Respiratory Adverse Events in Children Undergoing Tonsillectomies: A Randomized Controlled Trial.
Jang, YE; Ji, SH; Kang, P; Kim, EH; Kim, HS; Kim, JK; Kim, JT; Lee, JH; Lee, SH; Park, JB; Park, YH, 2023
)
1.54

Pharmacokinetics

Plasma levels and elimination half-life of tulobuterol were determined in ten healthy male volunteers after repeated dosing with 2 mg, twice daily, for seven days. The validated method has been successfully applied to a pharmacokinetic study of three doses of tulOButerol patch in rats for the first time. TulobuterOL was rapidly absorbed after inhalation, with a tmax of 0.

ExcerptReferenceRelevance
"Plasma levels and elimination half-life of tulobuterol, a new beta-adrenergic agonist, were determined in ten healthy male volunteers after repeated dosing with 2 mg, twice daily, for seven days."( Pharmacokinetics of the bronchodilator tulobuterol in man after repeated oral doses.
Chasseaud, LF; Wood, SG, 1986
)
0.8
"21 ng/mL, Tmax was 14."( Pharmacokinetics and pharmacodynamics of the tulobuterol patch, HN-078, in childhood asthma.
Akimoto, K; Ebisawa, M; Iikura, Y; Ishizu, H; Kabayama, H; Miura, K; Sakaguchi, N; Tsubaki, T; Uchiyama, H; Yagi, K, 1995
)
0.55
" The validated method has been successfully applied to a pharmacokinetic study of three doses of tulobuterol patch in rats for the first time."( Determination of tulobuterol in rat plasma using a liquid chromatography-tandem mass spectrometry method and its application to a pharmacokinetic study of tulobuterol patch.
Bi, K; Fang, L; Han, X; Hui, M; Ji, L; Li, Q; Liu, R, 2016
)
0.99

Bioavailability

The proposed method enables the unambiguous identification and quantification of tulobuterol for pharmacokinetic, bioavailability or bioequivalence studies.

ExcerptReferenceRelevance
" The proposed method enables the unambiguous identification and quantification of tulobuterol for pharmacokinetic, bioavailability or bioequivalence studies."( High-performance liquid chromatography electrospray ionization mass spectrometry determination of tulobuterol in rabbit's plasma.
Gong, G; Jiao, H; Liang, J; Tian, Y; Xu, F; Zhang, Z, 2005
)
0.77

Dosage Studied

Transdermal beta 2-agonist tulobuterol showed an improvement in FEV1, FVC and IC after dosing compared with those at baseline.

ExcerptRelevanceReference
" When chronic symptoms necessitate maintenance treatment, the frequency of dosing may become a deciding factor in the selection of a bronchodilator."( Tulobuterol in the management of obstructive airways disease in adults.
Patel, KR, 1985
)
1.71
" Biotransformations are determined by environmental or genetic factors and by the associated therapy and can change dramatically from one patient to another (interindividual variability) or for the same patient by multiple dosing (intra-individual variability)."( [Metabolism of beta-adrenergic substances. Therapeutic implications].
Brès, J; Bressolle, F; Clauzel, AM; Pistre, MC; Rachmat, H,
)
0.13
" The tulobuterol dosages were 30 and 40 mcg/kg twice daily; the terbutaline dosage was 75 mcg/kg three times daily."( Tulobuterol in childhood asthma: single dose ranging and repeated oral dose comparative studies.
Javier, MA; Noche, ML, 1986
)
2.23
"Plasma levels and elimination half-life of tulobuterol, a new beta-adrenergic agonist, were determined in ten healthy male volunteers after repeated dosing with 2 mg, twice daily, for seven days."( Pharmacokinetics of the bronchodilator tulobuterol in man after repeated oral doses.
Chasseaud, LF; Wood, SG, 1986
)
0.8
" Usually, oral dosage forms of beta 2-agonists have been used, but side effects such as palpitation and tremor have been reported because of excessive serum levels around Tmax."( [Development of transdermal formulation of tulobuterol for the treatment of bronchial asthma].
Kato, H; Nagata, O; Nakano, Y; Suzuki, T; Yamazaki, M, 2002
)
0.58
"Transdermal beta 2-agonist tulobuterol showed an improvement in FEV1, FVC and IC after dosing compared with those at baseline."( Comparison of bronchodilatory properties of transdermal and inhaled long-acting beta 2-agonists.
Akamatsu, K; Hirano, T; Ichikawa, T; Ichinose, M; Matsunaga, K; Minakata, Y; Nakanishi, M; Sugiura, H; Ueshima, K; Yamagata, T; Yanagisawa, S, 2008
)
0.64
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency0.01460.01846.806014.1254AID624148
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.53880.100020.879379.4328AID588453; AID588456
arylsulfatase AHomo sapiens (human)Potency1.90121.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency19.95260.035520.977089.1251AID504332
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency37.93300.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-2 adrenergic receptor Bos taurus (cattle)Kd0.13000.00061.47759.1200AID40694
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-2 adrenergic receptor Bos taurus (cattle)Concentration10.00001.00005.500010.0000AID40688
Beta-2 adrenergic receptor Bos taurus (cattle)KD app0.13000.03701.17744.4800AID40687
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (29)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
receptor-mediated endocytosisBeta-2 adrenergic receptor Bos taurus (cattle)
regulation of smooth muscle contractionBeta-2 adrenergic receptor Bos taurus (cattle)
positive regulation of MAPK cascadeBeta-2 adrenergic receptor Bos taurus (cattle)
negative regulation of G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptor Bos taurus (cattle)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-2 adrenergic receptor Bos taurus (cattle)
positive regulation of autophagosome maturationBeta-2 adrenergic receptor Bos taurus (cattle)
positive regulation of lipophagyBeta-2 adrenergic receptor Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (11)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
beta2-adrenergic receptor activityBeta-2 adrenergic receptor Bos taurus (cattle)
protein homodimerization activityBeta-2 adrenergic receptor Bos taurus (cattle)
norepinephrine bindingBeta-2 adrenergic receptor Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (15)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
early endosomeBeta-2 adrenergic receptor Bos taurus (cattle)
Golgi apparatusBeta-2 adrenergic receptor Bos taurus (cattle)
receptor complexBeta-2 adrenergic receptor Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (32)

Assay IDTitleYearJournalArticle
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID218847Change in Gibb's free energy at High affinity beta2- adrenoceptor in Chang living cells.1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Mapping of the beta 2-adrenoceptor on Chang liver cells. Differences between high- and low-affinity receptor states.
AID40686Affinity for cow beta-2 adrenergic receptor by measuring displacement (-)-[3H]dihydroalprenolol (DHA)1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Quantitative evaluation of the beta 2-adrenoceptor affinity of phenoxypropanolamines and phenylethanolamines.
AID218848Change in Gibb's free energy at Low affinity beta-2-adrenoceptor in the Chang living cells1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Mapping of the beta 2-adrenoceptor on Chang liver cells. Differences between high- and low-affinity receptor states.
AID40687Apparent binding affinity constant to beta-2 adrenergic receptor determined using [3H]DHA1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID40695Intrinsic activity was measured as concentration of beta-2 adrenergic receptor agonist required for cAMP production1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.
AID1873863Displacement of [3H]-CGP12,177 from immobilized Halo tag-fused beta2 adrenoceptor (unknown origin) expressed in Escherichia coli BL21 (DE3)
AID40688Concentration required for maximal (95-100%) beta-2 adrenergic receptor occupancy1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.
AID24177log(1/ISA) value of the compound1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.
AID40690Beta-2 adrenergic receptor intrinsic symphaticomimetic activity relative to salbutamol1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.
AID24440Calculated partition coefficient (clogP)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.
AID40694Affinity for cow beta-2 adrenergic receptor by measuring displacement (-)-[3H]dihydroalprenolol (DHA)1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Quantitative evaluation of the beta 2-adrenoceptor affinity of phenoxypropanolamines and phenylethanolamines.
AID218845Change in Gibb's free energy at Low affinity beta-2-adrenoceptor in the membranes of bovine skeletal muscle preparation1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Mapping of the beta 2-adrenoceptor on Chang liver cells. Differences between high- and low-affinity receptor states.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (136)

TimeframeStudies, This Drug (%)All Drugs %
pre-199035 (25.74)18.7374
1990's13 (9.56)18.2507
2000's36 (26.47)29.6817
2010's39 (28.68)24.3611
2020's13 (9.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 47.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index47.53 (24.57)
Research Supply Index5.24 (2.92)
Research Growth Index4.74 (4.65)
Search Engine Demand Index73.55 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (47.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials45 (31.47%)5.53%
Reviews9 (6.29%)6.00%
Case Studies3 (2.10%)4.05%
Observational0 (0.00%)0.25%
Other86 (60.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of Tulobuterol Patch Versus Placebo on the Occurrence of Respiratory Adverse Events in Children Undergoing Tonsillectomies [NCT04057469]182 participants (Actual)Interventional2019-12-20Completed
Study of Salmeterol (SN408D) for Adult Asthma - Clinical Study of Salmeterol Compared With Hokunalin (Tulobuterol) Tape - [NCT00950794]Phase 4367 participants (Actual)Interventional2003-09-30Completed
[NCT01465906]Phase 4160 participants (Anticipated)Interventional2010-11-30Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]